Despite concerns about organic growth, and what many pundits consider to be "diminishing productive balance" within its various business segments, Johnson & Johnson , whose stock is up close to 40% year to date, remains a top-notch player in Big Pharma. Just in case you were wondering.
I won't deny the fact that Johnson & Johnson's drug business continues to do most of the pulling, but I am -- nonetheless -- impressed by the meaningful improvements management has made in areas like orthopedics and medical devices.
While these improvements won't immediately threaten the market share established. JNJ.
No comments:
Post a Comment